These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9098659)

  • 21. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computer-based support system for formulary decisions.
    Senthilkumaran K; Shatz SM; Kalies RF
    Am J Hosp Pharm; 1987 Jun; 44(6):1362-6. PubMed ID: 3618613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool.
    Lim TM; Ibrahim MI
    Pharm Pract (Granada); 2012 Jul; 10(3):136-42. PubMed ID: 24155829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to select a best-value biological medicine? A practical model to support hospital pharmacists.
    Barbier L; Vandenplas Y; Boone N; Huys I; Janknegt R; Vulto AG
    Am J Health Syst Pharm; 2022 Nov; 79(22):2001-2011. PubMed ID: 36002245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An interactive computer system for formulary management using cost-effectiveness analysis.
    Lee JH; Glick HA; Kinosian B; Schulman KA
    MD Comput; 1995; 12(1):59-65. PubMed ID: 7854081
    [No Abstract]   [Full Text] [Related]  

  • 29. RXPERT: a prototype expert system for formulary decision making.
    Greer ML
    Ann Pharmacother; 1992 Feb; 26(2):244-50. PubMed ID: 1554940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing drug formularies for the "National Medical Holding" JSC.
    Akhmadyar NS; Khairulin BE; Amangeldy-Kyzy S; Ospanov MA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S51-2. PubMed ID: 26639709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision analysis in formulary decision making.
    Schechter CB
    Pharmacoeconomics; 1993 Jun; 3(6):454-61. PubMed ID: 10146880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The formulary decision-making process in a health maintenance organisation setting.
    Shepherd MD; Salzman RD
    Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Program eases decision making.
    Turri JJ
    Health Prog; 1988 Oct; 69(8):40-4. PubMed ID: 10290384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementing CER: what will it take?
    Biskupiak JE; Dunn JD; Holtorf AP
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S19-29. PubMed ID: 22663296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new spatial multi-criteria decision support tool for site selection for implementation of managed aquifer recharge.
    Rahman MA; Rusteberg B; Gogu RC; Lobo Ferreira JP; Sauter M
    J Environ Manage; 2012 May; 99():61-75. PubMed ID: 22322128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-criteria decision analysis tools for prioritising emerging or re-emerging infectious diseases associated with climate change in Canada.
    Cox R; Sanchez J; Revie CW
    PLoS One; 2013; 8(8):e68338. PubMed ID: 23950868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Life cycle impact assessment weights to support environmentally preferable purchasing in the United States.
    Gloria TP; Lippiatt BC; Cooper J
    Environ Sci Technol; 2007 Nov; 41(21):7551-7. PubMed ID: 18044540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
    Weekes LM; Day RO
    Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decision analysis in the formulary process.
    Kessler JM
    Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S5-8. PubMed ID: 9397231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.